AbCellera Biologics (ABCL) Investor Presentation - Slideshow

Corporate Overview - AbCellera had $754 million in cash, cash equivalents & marketable securities as of September 30, 2021[8] - AbCellera had $44 million in accounts & accrued receivable as of September 30, 2021[8] - AbCellera has over 10 years of expertise since it was founded in 2012[17] - AbCellera has invested $100Ms in tech development & acquisitions[17] - AbCellera has 380+ employees[17,34] Programs and Partnerships - AbCellera has 155 cumulative programs under contract[8] - AbCellera has 5 molecules in the clinic[8,41] - 72% of AbCellera's targets are difficult targets, while 28% are standard targets[21] Technology and Capabilities - AbCellera has 500K+ sq ft of facilities (total lab, office, & manufacturing spaces by 2024)[17] - AbCellera's technology stack includes SOURCE, SEARCH, DECODE, ANALYZE, and ENGINEER stages to optimize antibody discovery[19,32] - AbCellera's proprietary software, Celium™, is designed to visually explore data, interrogate parameters, and inform downstream selection and validation[90]